What is the 13F Pro Quality Score for EXAS?

13F Pro ranks EXACT SCIENCES CORP (EXAS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EXAS's current score at https://13fpro.ai/research/EXAS (free sign-up required for the full ranking).

Which hedge funds own the most EXAS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of EXAS include LINDEN ADVISORS, Weiss Asset Management, UBS OCONNOR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/EXAS as soon as new 13F filings post.

Where does 13F Pro source EXAS data?

All EXACT SCIENCES CORP fundamentals and ownership data come directly from SEC EDGAR. EXACT SCIENCES CORP files with the SEC under CIK 1124140. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EXAS in?

EXACT SCIENCES CORP (EXAS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EXAS research updated on 13F Pro?

EXAS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

EXACT SCIENCES CORP(EXAS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1124140 EXAS stock profile & AI dashboard →

13F Pro Quality Score

49.9/100

Rank #1,489 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

85.0/100

Profitability

28.0/100

Balance Sheet

27.9/100

Earnings Quality

30.0/100

Free Cash Flow

66.4/100

Revenue Scale

70.2/100

Dilution Risk

21.9/100

EXAS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for EXACT SCIENCES CORP (EXAS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EXAS at 49.9/100 on a 32-signal composite quality model, placing it at rank #1,489 of 2,879 stocks — the bottom half of the AI-ranked universe. EXAS scores in the top quartile across revenue growth (85.0). Areas of concern include balance sheet strength (27.9) and profitability (28.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), EXACT SCIENCES CORP reports quarterly revenue of $878.4M, net income of $-86.0M, an operating margin of -9.4%. Top institutional holders of EXAS by reported 13-F value include LINDEN ADVISORS, Weiss Asset Management, UBS OCONNOR, based on the most recent SEC filings. EXAS trades on the Nasdaq exchange and files with the SEC under CIK 1124140. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EXAS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXACT SCIENCES CORP directly from SEC EDGAR. EXACT SCIENCES CORP's 13F Pro composite quality score has ranged between 8 and 72 since 2021, currently 49.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about EXACT SCIENCES CORP

Quirks, history, and lore behind EXAS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. molecular diagnostics company · listed on Nasdaq · headquartered in Wisconsin · focused on early cancer detection.
2
The Numbers
Annual revenue in the roughly $700–800 million range, with a workforce of several thousand — big for a diagnostics company that sells essentially lab tests, not drugs.
3
The History
Founded in the early 2000s, it spent years developing a non-invasive stool-based colorectal cancer screening test before winning FDA approval and a major commercial breakthrough around 2014.
4
The Secret
It later expanded its portfolio by acquiring Genomic Health, adding oncology testing for breast and prostate cancer — transforming from a one-product company into a broader precision oncology platform.
5
The Lore
The Mayo Clinic was an early collaborator and partner in developing its flagship test, lending it serious scientific credibility before most people had ever heard of it.
6
The Giveaway
Its flagship product, Cologuard, lets you screen for colorectal cancer by mailing in a stool sample — no colonoscopy prep, no awkward doctor visit, just a blue box on your doorstep.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2025

$878.4M

Net Income

Q4 2025

$-86.0M

Free Cash Flow

Q4 2025

$120.4M

Operating Margin

Q4 2025

-9.4%

ROIC

Q4 2025

-3.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+17.7% YoY

$3.25BFY 2025

FY20 $1.49BFY22 $2.08BFY24 $2.76BFY25 $3.25B

Net Income

+79.8% YoY

$-207.9MFY 2025

FY20 $-848.5MFY22 $-623.5MFY24 $-1.03BFY25 $-207.9M

Operating Income

+80.3% YoY

$-206.3MFY 2025

FY20 $-768.0MFY22 $-593.5MFY24 $-1.05BFY25 $-206.3M

EPS (Diluted)

+80.3% YoY

$-1.10FY 2025

FY20 $-5.45FY22 $-3.54FY24 $-5.59FY25 $-1.10

Total Assets

-1.1% YoY

$5.86BFY 2025

FY20 $4.93BFY22 $6.23BFY24 $5.93BFY25 $5.86B

Total Debt

—FY 2025

FY20 $23.8MFY22 —FY24 —FY25 —

Op. Cash Flow

+133.4% YoY

$491.4MFY 2025

FY20 $136.5MFY22 $-223.6MFY24 $210.5MFY25 $491.4M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$3.25B +17.7%	$2.76B +32.4%	$2.08B +39.8%	$1.49B +70.2%	$876.3M +92.8%	$454.5M
Net Income	$-207.9M +79.8%	$-1.03B -65.0%	$-623.5M +26.5%	$-848.5M -910.2%	$-84.0M +52.0%	$-175.1M
Operating Income	$-206.3M +80.3%	$-1.05B -76.7%	$-593.5M +22.7%	$-768.0M -228.5%	$-233.8M -46.6%	$-159.5M
EPS (Diluted)	$-1.10 +80.3%	$-5.59 -57.9%	$-3.54 +35.0%	$-5.45 -236.4%	$-1.62	—
Total Assets	$5.86B -1.1%	$5.93B -4.8%	$6.23B +26.4%	$4.93B +40.5%	$3.51B +130.0%	$1.52B
Total Debt	—	—	—	$23.8M -8.1%	$25.8M +6.5%	$24.3M
Operating Cash Flow	$491.4M +133.4%	$210.5M +194.2%	$-223.6M -263.8%	$136.5M +218.7%	$-115.0M -65.9%	$-69.3M

Get alerted when EXAS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for EXACT SCIENCES CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EXAS

LINDEN ADVISORS LP
$244.9M238,106,000 sh
Weiss Asset Management LP
$134.7M129,000,000 sh
UBS OCONNOR LLC
$93.7M90,000,000 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$78.3M770,800 sh
Walleye Trading LLC
$61.0M600,700 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$60.1M591,600 sh
CAMDEN ASSET MANAGEMENT L P /CA
$52.7M51,385,000 sh
CAPSTONE INVESTMENT ADVISORS, LLC
$51.2M48,940,000 sh
VOYA INVESTMENT MANAGEMENT LLC
$48.4M46,305,000 sh
Man Group plc
$46.3M44,387,000 sh

Fund	Value	Shares
LINDEN ADVISORS LP	$244.9M	238,106,000
Weiss Asset Management LP	$134.7M	129,000,000
UBS OCONNOR LLC	$93.7M	90,000,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$78.3M	770,800
Walleye Trading LLC	$61.0M	600,700
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$60.1M	591,600
CAMDEN ASSET MANAGEMENT L P /CA	$52.7M	51,385,000
CAPSTONE INVESTMENT ADVISORS, LLC	$51.2M	48,940,000
VOYA INVESTMENT MANAGEMENT LLC	$48.4M	46,305,000
Man Group plc	$46.3M	44,387,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EXAS on your watchlist

Track score changes the day EXACT SCIENCES CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EXAS a good stock to buy?

13F Pro's AI-powered analysis of EXACT SCIENCES CORP (EXAS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EXAS are available on the EXAS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EXAS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EXAS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EXACT SCIENCES CORP's investment landscape.